Adverse effects of long-term proton pump inhibitor therapy

Digestive Diseases and Sciences

Volumn 56, Issue 4, 2011, Pages 931-950

  Sheen, Edward ^a   Triadafilopoulos, George ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Cancer; Fractures; Infections; Interactions; Malabsorption; Proton pump inhibitors; Safety

Indexed keywords

CALCIUM; CLOPIDOGREL; CYTOCHROME P450; ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BONE DENSITY; CALCIUM ABSORPTION; CAMPYLOBACTERIOSIS; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG SAFETY; FRACTURE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HUMAN; HYPERGASTRINEMIA; HYPOMAGNESEMIA; IMMUNOCOMPROMISED PATIENT; INTESTINE INFECTION; IRON DEFICIENCY; LISTERIOSIS; LONG TERM CARE; MALNUTRITION; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SALMONELLOSIS; SHIGELLOSIS; STOMACH CANCER; STOMACH CARCINOID; STOMACH POLYP; TERATOGENICITY; TREATMENT OUTCOME;

ANIMALS; ANTI-ULCER AGENTS; CARCINOID TUMOR; CONGENITAL ABNORMALITIES; DIARRHEA; DRUG INTERACTIONS; FEMALE; FRACTURES, BONE; HUMANS; IRON; MAGNESIUM; MALE; PNEUMONIA; PROTON PUMP INHIBITORS; RATS; STOMACH DISEASES; STOMACH NEOPLASMS; TREATMENT OUTCOME; VITAMIN B 12 DEFICIENCY;

EID: 79955608847     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1560-3     Document Type: Review

References (220)

1. Bamberg P, Caswell CM, Frame MH, Lam SK, Wong EC. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol. 1992;7:577-585. (Pubitemid 23025644)
2. Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. 1995;7:467-475.
3. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001;15:917-926. (Pubitemid 32578962)
4. Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757-766.
5. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200. (Pubitemid 41623288)
6. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009; 104:728-738.
7. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772-781. (Pubitemid 46854190)
8. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903.
9. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448-457.
10. Metz D. Proton pump inhibitor therapy: safety issues. In: Howden CW, ed. Advances in digestive disease. Bethesda, MD: AGA Institute Press; 2007:3-14.
11. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511. (Pubitemid 34465190)
12. Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl. 1991;188:1-7.
13. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992;6:399-406.
14. Schenk BE, Festen HP, Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SG. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther. 1996;10:541-545. (Pubitemid 26254797)
15. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422-430. (Pubitemid 28274845)
16. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162-167.
17. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57:422-428. (Pubitemid 38609284)
18. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008;27:491-497. (Pubitemid 351300856)
19. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110-1121. (Pubitemid 351614880)
20. Rozgony NR, Fang C, Kuczmarski MF, Bob H. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder. 2010;29:87-99.
21. Bellou A, Aimone-Gastin I, De Korwin JD, et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med. 1996;240:161-164. (Pubitemid 26308673)
22. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol. 2000;30:29-33. (Pubitemid 30032651)
23. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173-184.
24. Conrad ME, Schade SG. Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. Gastroenterology. 1968;55:35-45.
25. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92:108-116. (Pubitemid 8384452)
26. Golubov J, Flanagan P, Adams P. Inhibition of iron absorption by omeprazole in rat model. Dig Dis Sci. 1991;36:405-408.
27. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97:887-889. (Pubitemid 39249673)
28. Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81:1068-1071. (Pubitemid 11029686)
29. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291-1295. (Pubitemid 47300432)
30. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104:S5-S9.
31. Broeren MA, Geerdink EA, Vader HL, l Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151:755-756.
32. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69:338-341. (Pubitemid 352009025)
33. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol. 2011;27:180-185.
34. Doornebal J, Bijlsma R, Brouwer RM. An unknown but potentially serious side effect of proton pump inhibitors: hypomagnesaemia. Ned Tijdschr Geneeskd. 2009;153:A711.
35. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834-1836.
36. Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris). 2008;69:446-448.
37. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56:112-116.
38. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med. 2009;67:169-172.
39. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103:387-395.
40. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;102:2648-2654. (Pubitemid 350179329)
41. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56:168-174.
42. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.
43. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol. 2008;24:230-235. (Pubitemid 351322792)
44. Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006;127:525-537.
45. Mullin JM, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28:1317-1325.
46. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Best Pract Res Clin Gastroenterol. 2001;15:539-551. (Pubitemid 32590885)
47. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987;317:532-536. (Pubitemid 17123269)
48. Carr CJ, Shangraw RF. Nutritional and pharmaceutical aspects of calcium supplementation. Am Pharm. 1987;NS27:49-50. (54-47).
49. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol (Tokyo). 1998;44:869-875. (Pubitemid 29091153)
50. Chonan O, Takahashi R, Yasui H, Watanuki M. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo). 1998;44:473-481. (Pubitemid 28370958)
51. Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut. 1985;26:252-257. (Pubitemid 15054205)
52. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917-923.
53. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon WM, Melton LJ 3rd. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7:573-579.
54. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H + , K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21-25. (Pubitemid 23187327)
55. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H + -K + -ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38:123-125. (Pubitemid 16113857)
56. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896-904.
57. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364-368.
58. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-781. (Pubitemid 40897665)
59. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73:640-647. (Pubitemid 14156843)
60. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int. 1998;62:283-285. (Pubitemid 28139307)
61. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1922-1928. (Pubitemid 29358889)
62. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251-259.
63. Merriman NA, Putt ME, Metz DC, Yang YX. Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology. 2010;138:1330-1337.
64. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953. (Pubitemid 46021498)
65. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83. (Pubitemid 44306164)
66. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.
67. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-959.
68. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93-101.
69. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960. (Pubitemid 39411203)
70. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15:379-388. (Pubitemid 32187560)
71. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4:50-54.
72. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54-59. (Pubitemid 26239105)
73. Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995;26:1413-1418.
74. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14:74-81. (Pubitemid 30199109)
75. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118-1122. (Pubitemid 34508037)
76. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf. 2008;31:627-636. (Pubitemid 351861955)
77. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18:847-851. (Pubitemid 37323651)
78. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950-955. (Pubitemid 46762758)
79. Gau J. Does Gastric Acid-Suppressive Therapy Increase the Risk of Pneumonia in Older Adults? Presented at AGS Meeting; 2007.
80. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391-398.
81. Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther. 1996;10:359-366. (Pubitemid 26174911)
82. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19:792-802.
83. Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:7-16. (Pubitemid 15105118)
84. Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1:672-674. (Pubitemid 10131679)
85. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28:96-107. (Pubitemid 17231555)
86. Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8:574-581.
87. Cothran DS, Borowitz SM, Sutphen JL, Dudley SM, Donowitz LG. Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol. 1997;17:383-388. (Pubitemid 127454932)
88. Holt TL, Coombes ID, Pillans PI, Scott IA. Neutropenia associated with omeprazole. Med J Aust. 1999;170:141-142.
89. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. J Biol Chem. 1994;269:9952-9956. (Pubitemid 24196608)
90. Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed). 1984;289:717-719. (Pubitemid 14009890)
91. Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455-460. (Pubitemid 24131238)
92. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35:23-26. (Pubitemid 24059466)
93. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26:121-132. (Pubitemid 36188562)
94. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50:366-372.
95. Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11:887-897.
96. Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Characteristics of diarrhoea in 10, 008 users of lansoprazole in daily practice: which co-factors contribute? Pharmacoepidemiol Drug Saf. 2002;11:703-708.
97. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8:571-574.
98. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ. 1996;312:414-415.
99. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136:1225-1234.
100. Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. 1994;308:176. (Pubitemid 24049052)
101. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418-1423. (Pubitemid 350181606)
102. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134:617-626.
103. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817-e820. (Pubitemid 46071346)
104. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047-2056. (quiz 2057).
105. Evans CA, Gilman RH, Rabbani GH, Salazar G, Ali A. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg. 1997;91:681-685. (Pubitemid 28019915)
106. Ho JL, Shands KN, Friedland G, Eckind P, Fraser DW. An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med. 1986;146:520-524. (Pubitemid 16067899)
107. Larner AJ, Hamilton MI. Review article: infective complications of therapeutic gastric acid inhibition. Aliment Pharmacol Ther. 1994;8:579-584. (Pubitemid 24381356)
108. Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:17-23. (Pubitemid 15105119)
109. Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol. 1998;28:149-157.
110. Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol. 1995;30:775-778.
111. Cadranel JF, Eugene C. Another example of Strongyloides stercoralis infection associated with cimetidine in an immunosuppressed patient. Gut. 1986;27:1229. (Pubitemid 16002626)
112. Ainley CC, Clarke DG, Timothy AR, Thompson RP. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut. 1986;27:337-338. (Pubitemid 16101908)
113. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96:94-102. (Pubitemid 40320612)
114. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339-1350. (Pubitemid 36748921)
115. Severe C. lostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201-1205.
116. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis. 1985;151:355-361. (Pubitemid 15155304)
117. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104:S10-S16.
118. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43:1272-1276. (Pubitemid 44706452)
119. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62:388-396. (Pubitemid 351984787)
120. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784-790.
121. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am. 1990;19:141-153. (Pubitemid 20232541)
122. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217-1221. (Pubitemid 44277346)
123. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:651-668. (Pubitemid 30352732)
124. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther. 1998;12:605-612. (Pubitemid 28327956)
125. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116:239-247. (Pubitemid 29055344)
126. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80-87. (87 e81).
127. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45:389-394.
128. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000;157:747-754. (Pubitemid 32109367)
129. Kinoshita Y, Tojo M, Yano T, et al. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. Gastrointest Endosc. 1993;39:161-163. (Pubitemid 23139708)
130. Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch. 2000;437:581-590. (Pubitemid 32003087)
131. Stolte M, Sticht T, Eidt S, Ebert D, Finkenzeller G. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy. 1994;26:659-665. (Pubitemid 24361207)
132. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol. 1997;92:1858-1860.
133. Jackson FW, Gordon S. Regression of fundic gland polyps after discontinuation of omeprazole [abstract]. Am J Gastroenterol Clin Biol. 1998;9:A121.
134. Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci. 1996;41:2039-2047. (Pubitemid 26366806)
135. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684-690. (Pubitemid 30445471)
136. Sakai N, Tatsuta M, Hirasawa R, et al. Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps. Dig Dis Sci. 1998;43:766-772. (Pubitemid 28176465)
137. Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615-621. (Pubitemid 28491966)
138. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust. 1992;157:287-288.
139. Jalving M, Koornstra JJ, Wesseling J, Boezen HM SDEJ, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341-1348. (Pubitemid 44571564)
140. Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc. 2002;55:600-602. (Pubitemid 41123524)
141. Naegels S, Urbain D. Omeprazole and fundic gland polyps. Am J Gastroenterol. 1998;93:855.
142. Stolte M, Bethke B, Seifert E, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol. 1995;33:146-149.
143. Van Vlierberghe H, De Vos M, De Cock G, Cuvelier C, Elewaut A. Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastroenterol Belg. 1997;60:240-242. (Pubitemid 27489437)
144. Collins S, Tydd T. Gastric polyps and long-term omeprazole [abstract]. J Gastroenterol Hepatology. 1998.
145. Mogadam M, Houk R. Long-term use of omeprazole is associated with development of benign epithelial gastric polyps [abstract]. Am J Gastroenterol. 1996;91:A151.
146. Reekmans A, Naegels S, Reynaert H, Urbain D. Fundic gland polyps and chronic PPI treatment: a prospective study [abstract]. Gastroenterology. 2001.
147. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol. 2001;116:716-720. (Pubitemid 34453213)
148. Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology. 1993;105:1590-1591. (Pubitemid 23315344)
149. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158:1005-1010. (Pubitemid 32221792)
150. Jalving M, Koornstra JJ, Boersma-van Ek W, et al. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol. 2003;38:916-922. (Pubitemid 37153618)
151. Torbenson M, Lee JH, Cruz-Correa M, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol. 2002;15:718-723. (Pubitemid 34787307)
152. Abraham SC, Park SJ, Cruz-Correa M, et al. Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps. Am J Clin Pathol. 2004;122:740-746. (Pubitemid 39434755)
153. Abraham SC, Park SJ, Mugartegui L, Hamilton SR, Wu TT. Sporadic fundic gland polyps with epithelial dysplasia : evidence for preferential targeting for mutations in the adenomatous polyposis coli gene. Am J Pathol. 2002;161:1735-1742. (Pubitemid 35265531)
154. Wei J, Chiriboga L, Yee H, et al. Altered cellular distribution of tuberin and glucocorticoid receptor in sporadic fundic gland polyps. Mod Pathol. 2002;15:862-869. (Pubitemid 34919779)
155. Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol. 2002;97:298-301. (Pubitemid 34160753)
156. Svendsen JH, Dahl C, Svendsen LB, Christiansen PM. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol. 1986;21:16-20. (Pubitemid 16177455)
157. Carter DC. Cancer after peptic ulcer surgery. Gut. 1987;28:921-923. (Pubitemid 17119259)
158. Caygill CP, Hill MJ, Kirkham JS, Northfield TC. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet. 1986;1:929-931. (Pubitemid 16143070)
159. Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992;51:102-114.
160. Fiocca R, Villani L, Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol. 1992;420:489-498.
161. Rubin CE. Are there three types of Helicobacter pylori gastritis? Gastroenterology. 1997;112:2108-2110.
162. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer. 1994;74:556-564.
163. Weeks DL, Eskandari S, Scott DR, Sachs G. A H + -gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science. 2000;287:482-485.
164. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90:1401-1406.
165. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36:12-16.
166. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022. (Pubitemid 26123777)
167. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology. 1999;117:319-326.
168. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639-647.
169. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.
170. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825. (Pubitemid 47206706)
171. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
172. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005;19:1610-1612. (Pubitemid 41719529)
173. Waldum HL, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. Dig Dis Sci. 2005;50:S39-S44. (Pubitemid 41380797)
174. Robinson M. Current perspectives on hypergastrinemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther. 1999;13:5-10. (Pubitemid 29467291)
175. Bardram L, Thomsen P, Stadil F. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome. Digestion. 1986;35:116-122. (Pubitemid 17197939)
176. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985;88:638-648. (Pubitemid 15130649)
177. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994-1006. (Pubitemid 23090750)
178. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669. (Pubitemid 30171615)
179. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992;51:82-92.
180. Solcia E, Rindi G, Havu N, Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl. 1989;166:129-137 (discussion 138-129).
181. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole-with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl. 1986;118:31-38. (Pubitemid 16107567)
182. Lee H, Hakanson R, Karlsson A, Mattsson H, Sundler F. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. Digestion. 1992;51:125-132.
183. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology. 1991;100:311-319.
184. Poynter D, Pick CR, Harcourt RA, et al. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut. 1985;26:1284-1295.
185. Hakanson R, Larsson LI, Liedberg G, Oscarson J, Sundler F, Vang J. Effects of antrectomy or porta-caval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study. J Physiol. 1976;259:785-800.
186. Simonsson M, Eriksson S, Hakanson R, et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol. 1988;23:1089-1099.
187. Watson SA, Durrant LG, Crosbie JD, Morris DL. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer. 1989;43:692-696. (Pubitemid 19110107)
188. Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut. 1997;41:330-332. (Pubitemid 27428191)
189. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology. 1998;115:275-280. (Pubitemid 28363419)
190. Singh M, Dhindsa G, Friedland S, Triadafilopoulos G. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther. 2007;26:1051-1061. (Pubitemid 47416294)
191. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748-754. (Pubitemid 47374135)
192. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755-760. (Pubitemid 47385871)
193. van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966-973. (Pubitemid 351501082)
194. McCarthy DM, McLaughlin T, Yazdani C, El Serag HB, Griffis DL. Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: a cohort study. Gastroenterology. 2002;122(4)(Suppl. 1):A210 (abstract S1345).
195. Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther. 2003;17:1015-1019. (Pubitemid 36560801)
196. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769-784. (Pubitemid 44352242)
197. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951.
198. Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie. 2002;57:595-601. (Pubitemid 35025465)
199. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13:345-349.
200. Alkhatib AA, Elkhatib FA, Khatib OF. Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations? Am J Gastroenterol. 2010;105:1211.
201. Bhatt DL, Cryer B, Contant CF, et al. COGENT. COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel [abstract]. Transvascular Cardiovascular Therapeutics Annual Meeting; September 24, 2009; San Francisco, CA. http://www.slideshare.net/ flaviog/bhnt.
202. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
203. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997.
204. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322-2329.
205. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152:337-345.
206. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170:704-710.
207. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
208. HA Stockl KM, Solow BK, Addiego JE, Ramsey S. Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction - reply. Arch Intern Med. 2010;170:1508.
209. Rey E, Rodriguez-Artalejo F, Herraiz MA, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol. 2007;102:2395-2400. (Pubitemid 47631774)
210. Diav-Citrin O, Arnon J, Shechtman S, et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther. 2005;21:269-275. (Pubitemid 40278364)
211. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol. 1998;105:877-881. (Pubitemid 28423504)
212. Kallen BA. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;96:63-68. (Pubitemid 32331852)
213. Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998;179:727-730. (Pubitemid 28447254)
214. Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther. 1999;13:1085-1089. (Pubitemid 29374110)
215. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002;47:1526-1529. (Pubitemid 34753932)
216. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999;150:476-481. (Pubitemid 29407231)
217. Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104:1541-1545 (quiz 1540, 1546).
218. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363:2114-2123.
219. Mitchell AA. Studies of drug-induced birth defects, chapter 32. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. New York: Wiley; 2005:501-515.
220. Dehlink E, Yen E, Leichtner AM, Hait EJ, Fiebiger E. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy. 2009;39:246-253.